Clinical Trial

Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a prospective, multicenter, open-label, phase Ib/II clinical study to evaluate the safety and efficacy of golidocitinib combined with mitoxantrone hydrochloride liposome or chidamide in the treatment of relapsed or refractory peripheral T-cell lymphoma
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-23.
Status change: Not Yet Recruiting → Recruiting 2025-12-26
Trial Details
NCT Number NCT07093710
Lead Sponsor Sun Yat-sen University
Conditions Peripheral T Cell Lymphoma
Enrollment 101 participants
Start Date 2025-08-27
Primary Completion 2027-08-01 (estimated)
Study Completion 2029-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-31